Kalaris Therapeutics Inc
General ticker "KLRS" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $153.9M (TTM average)
Kalaris Therapeutics Inc does not follow the US Stock Market performance with the rate: -27.1%.
Estimated limits based on current volatility of 3.8%: low 2.67$, high 2.88$
Factors to consider:
- Total employees count: 20 as of 2025
- Company does not operate outside US (retrieved using AI)
- Top business risk factors: Operating losses, Clinical trial failure, Regulatory and compliance, Intellectual property risks, Sales and marketing challenges
- Current price 45.9% below estimated low
- Earnings for 6 months up through Q2 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [4.99$, 15.31$]
- 2026-12-31 to 2027-12-31 estimated range: [2.96$, 9.55$]
Financial Metrics affecting the KLRS estimates:
- Negative: with PPE of -2.2 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: negative Operating cash flow
- Negative: Investing cash flow per share per price, % of -14.02 <= -11.23
- Negative: 58.56 < Shareholder equity ratio, % of 64.74 <= 69.38
- Positive: Interest expense per share per price, % of 1.03 <= 1.42
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Negative: Industry earnings per price (median), % of -15.99 <= 0
Short-term KLRS quotes
Long-term KLRS plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $199.90MM | $65.44MM | $46.15MM |
| Operating Income | $-199.90MM | $-65.44MM | $-46.15MM |
| Non-Operating Income | $9.36MM | $6.67MM | $2.71MM |
| Interest Expense | $0.00MM | $0.00MM | $1.44MM |
| R&D Expense | $133.07MM | $12.34MM | $30.75MM |
| Income(Loss) | $-190.54MM | $-58.77MM | $-43.44MM |
| Taxes | $-0.13MM | $0.00MM | $0.00MM |
| Net Income(Loss)* | $-190.42MM | $-58.77MM | $-43.44MM |
| Stockholders Equity | $145.78MM | $113.31MM | $78.81MM |
| Assets | $190.80MM | $118.55MM | $121.74MM |
| Operating Cash Flow | $-124.45MM | $-67.70MM | $-38.37MM |
| Capital expenditure | $0.00MM | $0.00MM | $0.20MM |
| Investing Cash Flow | $37.98MM | $95.00MM | $-19.72MM |
| Financing Cash Flow | $70.50MM | $0.02MM | $155.01MM |
| Earnings Per Share** | $-42.09 | $-11.73 | $-2.85 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.